Ravi Vij, MD, MBA, Washington University Medical School, St Louis, MO, outlines the use of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma (MM). Dr Vij goes on to discuss the choice between an antibody-drug conjugate, or CAR-T cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).